Australian Institute for Bioengineering and Nanotechnology, Centre for Biomolecular Engineering, The University of Queensland, St Lucia, QLD 4072, Australia.
Biotechnol Bioeng. 2013 Sep;110(9):2343-51. doi: 10.1002/bit.24907. Epub 2013 Apr 22.
Modularization of a peptide antigen for presentation on a microbially synthesized murine polyomavirus (MuPyV) virus-like particle (VLP) offers a new alternative for rapid and low-cost vaccine delivery at a global scale. In this approach, heterologous modules containing peptide antigenic elements are fused to and displayed on the VLP carrier, allowing enhancement of peptide immunogenicity via ordered and densely repeated presentation of the modules. This study addresses two key engineering questions pertaining to this platform, exploring the effects of (i) pre-existing carrier-specific immunity on modular VLP vaccine effectiveness and (ii) increase in the antigenic element number per VLP on peptide-specific immune response. These effects were studied in a mouse model and with modular MuPyV VLPs presenting a group A streptococcus (GAS) peptide antigen, J8i. The data presented here demonstrate that immunization with a modular VLP could induce high levels of J8i-specific antibodies despite a strong pre-existing anti-carrier immune response. Doubling of the J8i antigenic element number per VLP did not enhance J8i immunogenicity at a constant peptide dose. However, the strategy, when used in conjunction with increased VLP dose, could effectively increase the peptide dose up to 10-fold, leading to a significantly higher J8i-specific antibody titer. This study further supports feasibility of the MuPyV modular VLP vaccine platform by showing that, in the absence of adjuvant, modularized GAS antigenic peptide at a dose as low as 150 ng was sufficient to raise a high level of peptide-specific IgGs indicative of bactericidal activity.
将肽抗原模块化,用于展示在微生物合成的小鼠多瘤病毒 (MuPyV) 病毒样颗粒 (VLP) 上,为在全球范围内快速、低成本地提供疫苗提供了一种新的选择。在这种方法中,含有肽抗原元件的异源模块融合并展示在 VLP 载体上,通过模块的有序和密集重复呈现来增强肽的免疫原性。本研究解决了与该平台相关的两个关键工程问题,探讨了 (i) 载体特异性固有免疫对模块化 VLP 疫苗效果的影响和 (ii) 每个 VLP 上抗原元件数量增加对肽特异性免疫反应的影响。这些影响在小鼠模型中进行了研究,并使用展示 A 组链球菌 (GAS) 肽抗原 J8i 的模块化 MuPyV VLP 进行了研究。这里呈现的数据表明,尽管存在强烈的固有抗载体免疫反应,免疫接种模块化 VLP 仍能诱导高水平的 J8i 特异性抗体。每个 VLP 上 J8i 抗原元件数量增加一倍并不能在恒定肽剂量下增强 J8i 的免疫原性。然而,当与增加的 VLP 剂量结合使用时,该策略可有效将肽剂量增加 10 倍,导致 J8i 特异性抗体滴度显著提高。本研究进一步通过显示在没有佐剂的情况下,低至 150ng 的模块化 GAS 抗原性肽足以引起高水平的肽特异性 IgG,表明具有杀菌活性,从而进一步支持 MuPyV 模块化 VLP 疫苗平台的可行性。